The A30P alpha-synuclein transgenic mouse model was one of the first genetic models of Parkinson's disease, expressing the A30P mutation linked to familial PD. This model demonstrates age-dependent α-synuclein aggregation and progressive motor dysfunction.
| Component |
Details |
| Promoter |
PDGF-β (platelet-derived growth factor beta) |
| Gene |
Human SNCA with A30P mutation |
| Insertion |
Single copy, random integration |
| Expression |
Neuron-specific, moderate levels |
The A30P (Ala30Pro) mutation in SNCA was one of the first point mutations identified in familial PD:
- Location: Residue 30 in the NAC (non-Aβ component) domain
- Effect: Increases α-synuclein aggregation propensity
- Inheritance: Autosomal dominant
- Penetrance: High but variable
The A30P mutation accelerates α-synuclein aggregation through:
- Nucleation enhancement: The proline residue disrupts α-helical structure, promoting β-sheet formation
- Oligomerization: Faster formation of soluble oligomers
- Fibril formation: Accelerated maturation into insoluble fibrils
- Cellular toxicity: Oligomers more toxic than fibrils
- Proteostasis: Impaired ubiquitin-proteasome system
- Autophagy: Dysregulated macroautophagy and CMA
- Mitochondria: Altered mitochondrial function and dynamics
- Synaptic function: Impaired synaptic vesicle cycling
- Cytoplasmic inclusions: pSer129-positive inclusions in neurons
- Lewy body-like structures: Characteristic round inclusions
- Neuritic pathology: Dystrophic neurites with α-synuclein deposits
- Progressive spread: Pathology increases with age
- Dopaminergic neuron loss: Moderate loss in substantia nigra (20-40%)
- Striatal terminals: Reduced dopaminergic innervation
- Neuroinflammation: Microglial activation in affected regions
| Age |
Motor Phenotype |
Tests |
| 3-6 months |
Minimal |
Baseline |
| 6-12 months |
Mild impairment |
Rotarod, pole test |
| 12-18 months |
Moderate deficits |
Cylinder, gait |
| 18+ months |
Severe impairment |
Rotarod failure |
The A30P model enables testing of:
- Anti-aggregation compounds: Targeting oligomerization
- Autophagy enhancers: Trehalose, rapamycin
- Immunotherapies: Anti-α-synuclein antibodies
- Neuroprotective agents: Mitochondrial protectants
- Aggregation pathways: Characterize oligomer and fibril species
- Spread mechanisms: Inter-neuronal transmission
- Cellular vulnerability: Why dopaminergic neurons are selectively affected
¶ Advantages and Limitations
- Genetic model: Expresses known disease-causing mutation
- Progressive phenotype: Age-dependent deterioration
- Motor deficits: Clear behavioral readouts
- Well-characterized: Extensive literature base
- Non-physiological expression: PDGF promoter drives abnormal expression pattern
- Variable penetrance: Not all animals develop severe pathology
- Limited neuronal loss: Less neurodegeneration than toxin models
- Late onset: Phenotype takes 12+ months to develop
- Kahle et al., 2000 - Hyperphosphorylation and aggregation of A30P α-synuclein
- Masliah et al., 2000 - Neurodegeneration in A30P transgenic mice
- Miller et al., 2004 - Behavioral characterization of A30P mice
- Bendor et al., 2013 - α-Synuclein function and dysfunction